Antibiotics Are Man's Greatest Invention

The mycobacterial cell envelope — a moving target

  • 1.

    Cambier, C. J., Falkow, S. & Ramakrishnan, L. Host evasion and exploitation schemes of Mycobacterium tuberculosis. Cell 159, 1497–1509 (2014).

  • 2.

    Lin, P. L. et al. Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing. Nat. Med. 20, 75–79 (2014). This transformational article shows that human infections are variable at the level of the granuloma, with each granuloma progressing separately.

  • 3.

    Gideon, H. P. et al. Variability in tuberculosis granuloma T cell responses exists, but a balance of pro- and anti-inflammatory cytokines is associated with sterilization. PLOS Pathog. 11, e1004603 (2015).

  • 4.

    Malherbe, S. T. et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat. Med. 22, 1094–1100 (2016).

  • 5.

    Chiaradia, L. et al. Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane. Sci. Rep. 7, 12807 (2017).

  • 6.

    Hoffmann, C., Leis, A., Niederweis, M., Plitzko, J. M. & Engelhardt, H. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc. Natl Acad. Sci. USA 105, 3963–3967 (2008).

  • 7.

    Zuber, B. et al. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J. Bacteriol. 190, 5672–5680 (2008). This study and Hoffmann et al. (2008) produce the first high resolution cryogenic electron microscopy datasets that verify the existence of the mycobacterial outer membrane (the mycomembrane) and the spatial organization of the other envelope layers.

  • 8.

    Minnikin, D. E. et al. Pathophysiological implications of cell envelope structure in Mycobacterium tuberculosis and related taxa. in Tuberculosis – Expanding Knowl. (ed. Ribon, W.) (InTech, 2015).

  • 9.

    Daffé, M. & Etienne, G. The capsule of Mycobacterium tuberculosis and its implications for pathogenicity. Tuber. Lung Dis. 79, 153–169 (1999).

  • 10.

    Manganelli, R. Sigma factors: key molecules in Mycobacterium tuberculosis physiology and virulence. Microbiol. Spectr. (2014).

  • 11.

    Parish, T. Two-component regulatory systems of mycobacteria. Microbiol. Spectr. (2014).

  • 12.

    Prisic, S. & Husson, R. N. Mycobacterium tuberculosis serine/threonine protein kinases. Microbiol. Spectr. (2014).

  • 13.

    Xi, X., Han, X., Li, L. & Zhao, Z. Identification of a new tuberculosis antigen recognized by γδ t cell receptor. Clin. Vaccine Immunol. 20, 530–539 (2013).

  • 14.

    Bacon, J. et al. Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix. PLOS ONE 9, e87329 (2014).

  • 15.

    Sarathy, J., Dartois, V., Dick, T. & Gengenbacher, M. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57, 1648–1653 (2013). This article is the first to show what has long been suspected — that cells in stasis are less permeable to antibiotics.

  • 16.

    Seiler, P. et al. Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J. Infect. Dis. 188, 1326–1331 (2003). This observational study with human and mouse tissue sections shows that M. tuberculosis cells in latent infection have a cell wall that is different from that observed during active infection.

  • 17.

    Xie, Z., Siddiqi, N. & Rubin, E. J. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 49, 4778–4780 (2005).

  • 18.

    Xu, W. et al. Chemical genetic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 61, e01334-17 (2017).

  • 19.

    Alderwick, L. J., Harrison, J., Lloyd, G. S. & Birch, H. L. The mycobacterial cell wall—peptidoglycan and arabinogalactan. Cold Spring Harb. Perspect. Med. 5, (2015).

  • 20.

    Guerin, M. E., Korduláková, J., Alzari, P. M., Brennan, P. J. & Jackson, M. Molecular basis of phosphatidyl-myo-inositol mannoside biosynthesis and regulation in mycobacteria. J. Biol. Chem. 285, 33577–33583 (2010).

  • 21.

    Marrakchi, H., Lanéelle, M.-A. & Daffé, M. Mycolic acids: structures, biosynthesis, and beyond. Chem. & Biol. 21, 67–85 (2014).

  • 22.

    Mishra, A. K., Driessen, N. N., Appelmelk, B. J. & Besra, G. S. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host–pathogen interaction. FEMS Microbiol. Rev. 35, 1126–1157 (2011).

  • 23.

    Brennan, P. J. & Nikaido, H. The envelope of mycobacteria. Annu. Rev. Biochem. 64, 29–63 (1995).

  • 24.

    Cook, G. M. et al. Physiology of mycobacteria. Adv. Microb. Physiol. 55, 81–319 (2009).

  • 25.

    Kieser, K. J. & Rubin, E. J. How sisters grow apart: mycobacterial growth and division. Nat. Rev. Microbiol. 12, 550–562 (2014).

  • 26.

    Aldridge, B. B. et al. Asymmetry and aging of mycobacterial cells leads to variable growth and antibiotic susceptibility. Science 335, 100–104 (2012).

  • 27.

    Santi, I., Dhar, N., Bousbaine, D., Wakamoto, Y. & McKinney, J. D. Single-cell dynamics of the chromosome replication and cell division cycles in mycobacteria. Nat. Commun. 4, 2470 (2013).

  • 28.

    Hayashi, J. M. et al. Spatially distinct and metabolically active membrane domain in mycobacteria. Proc. Natl Acad. Sci. USA 113, 5400–5405 (2016). This article demonstrates, for the first time, the existence of an organelle in mycobacteria, that appears to be important for synthesis of the cell wall.

  • 29.

    Jani, C. et al. Regulation of polar peptidoglycan biosynthesis by Wag31 phosphorylation in mycobacteria. BMC Microbiol. 10, 327 (2010).

  • 30.

    Kang, C.-M., Nyayapathy, S., Lee, J.-Y., Suh, J.-W. & Husson, R. N. Wag31, a homologue of the cell division protein DivIVA, regulates growth, morphology and polar cell wall synthesis in mycobacteria. Microbiology 154, 725–735 (2008).

  • 31.

    Meniche, X. et al. Subpolar addition of new cell wall is directed by DivIVA in mycobacteria. Proc. Natl Acad. Sci. USA 111, E3243–E3251 (2014).

  • 32.

    Baer, C. E., Iavarone, A. T., Alber, T. & Sassetti, C. M. Biochemical and spatial coincidence in the provisional Ser/Thr protein kinase interaction network of Mycobacterium tuberculosis. J. Biol. Chem. 289, 20422–20433 (2014).

  • 33.

    Botella, H. et al. Distinct spatiotemporal dynamics of peptidoglycan synthesis between Mycobacterium smegmatis and Mycobacterium tuberculosis. mBio 8, e01183-17 (2017).

  • 34.

    Kuru, E., Tekkam, S., Hall, E., Brun, Y. V. & Van Nieuwenhze, M. S. Synthesis of fluorescent d-amino acids and their use for probing peptidoglycan synthesis and bacterial growth in situ. Nat. Protoc. 10, 33–52 (2015).

  • 35.

    Thanky, N. R., Young, D. B. & Robertson, B. D. Unusual features of the cell cycle in mycobacteria: polar-restricted growth and the snapping-model of cell division. Tuberculosis 87, 231–236 (2007).

  • 36.

    Baranowski, C. et al. Maturing Mycobacterium smegmatis peptidoglycan requires non-canonical crosslinks to maintain shape. eLife 7, e37516 (2018). This article makes a strong argument, through meticulous though necessarily indirect experiments, that the chemical structure of peptidoglycan varies across the length of the cell.

  • 37.

    Carel, C. et al. Mycobacterium tuberculosis proteins involved in mycolic acid synthesis and transport localize dynamically to the old growing pole and septum. PLOS ONE 9, e97148 (2014).

  • 38.

    Hodges, H. L., Brown, R. A., Crooks, J. A., Weibel, D. B. & Kiessling, L. L. Imaging mycobacterial growth and division with a fluorogenic probe. Proc. Natl Acad. Sci. USA 115, 5271–5276 (2018).

  • 39.

    Zhou, X. et al. Sequential assembly of the septal cell envelope prior to V snapping in Corynebacterium glutamicum. Nat. Chem. Biol. 15, 221 (2019). This thorough article shows that the cell wall core is assembled in an ordered fashion: the peptidoglycan layer is constructed before the mycolic acid layer (see Supplementary information for the mycobacterial data).

  • 40.

    Rego, E. H., Audette, R. E. & Rubin, E. J. Deletion of a mycobacterial divisome factor collapses single-cell phenotypic heterogeneity. Nature 546, 153–157 (2017).

  • 41.

    Eskandarian, H. A. et al. Division site selection linked to inherited cell surface wave troughs in mycobacteria. Nat. Microbiol. 2, 17094 (2017).

  • 42.

    Joyce, G. et al. Cell division site placement and asymmetric growth in mycobacteria. PLOS ONE 7, e44582 (2012).

  • 43.

    Singh, B. et al. Asymmetric growth and division in Mycobacterium spp.: compensatory mechanisms for non-medial septa. Mol. Microbiol. 88, 64–76 (2013).

  • 44.

    Wu, M.-L., Gengenbacher, M. & Dick, T. Mild nutrient starvation triggers the development of a small-cell survival morphotype in mycobacteria. Front. Microbiol. 7, (2016).

  • 45.

    Hayashi, J. M. et al. Stress-induced reorganization of the mycobacterial membrane domain. mBio 9, e01823-17 (2018).

  • 46.

    Gill, W. P. et al. A replication clock for Mycobacterium tuberculosis. Nat. Med. 15, 211–214 (2009).

  • 47.

    Ford, C. B. et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 43, 482–486 (2011).

  • 48.

    Zhang, Y. J. et al. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell 155, 1296–1308 (2013).

  • 49.

    Wayne, L. G. & Hayes, L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64, 8 (1996).

  • 50.

    Bansal-Mutalik, R. & Nikaido, H. Mycobacterial outer membrane is a lipid bilayer and the inner membrane is unusually rich in diacyl phosphatidylinositol dimannosides. Proc. Natl Acad. Sci. USA 111, 4958–4963 (2014).

  • 51.

    Fukuda, T. et al. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. mBio 4, e00472-12 (2013).

  • 52.

    Koul, A., Herget, T., Klebl, B. & Ullrich, A. Interplay between mycobacteria and host signalling pathways. Nat. Reviews Microbiol. 2, 189–202 (2004).

  • 53.

    Glass, L. N. et al. Mycobacterium tuberculosis universal stress protein Rv2623 interacts with the putative ATP binding cassette (ABC) transporter Rv1747 to regulate mycobacterial growth. PLOS Pathog. 13, e1006515 (2017).

  • 54.

    Crellin, P. K. et al. Mutations in pime restore lipoarabinomannan synthesis and growth in a Mycobacterium smegmatis IpqW mutant. J. Bacteriol. 190, 3690–3699 (2008). This article describes the genetic mechanisms by which the PIM and LAM lipids, despite being biosynthetically linked, can be differentially regulated.

  • 55.

    Drumm, J. E. et al. Mycobacterium tuberculosis universal stress protein Rv2623 regulates bacillary growth by ATP-binding: requirement for establishing chronic persistent infection. PLOS Pathog. 5, e1000460 (2009).

  • 56.

    Pang, X. et al. Evidence for complex interactions of stress-associated regulons in an mprAB deletion mutant of Mycobacterium tuberculosis. Microbiology 153, 1229–1242 (2007).

  • 57.

    Rustad, T. R., Harrell, M. I., Liao, R. & Sherman, D. R. The enduring hypoxic response of Mycobacterium tuberculosis. PLOS ONE 3, e1502 (2008).

  • 58.

    Nigou, J. et al. Mannan chain length controls lipoglycans signaling via and binding to TLR2. J. Immunol. 180, 6696–6702 (2008).

  • 59.

    Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A. & Duncan, K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43, 717–731 (2002).

  • 60.

    Peterson, E. J. et al. Path-seq identifies an essential mycolate remodeling program for mycobacterial host adaptation. Mol. Syst. Biol. 15, e8584 (2019).

  • 61.

    Papavinasasundaram, K. G. et al. Deletion of the Mycobacterium tuberculosis pknH gene confers a higher bacillary load during the chronic phase of infection in BALB/c mice. J. Bacteriol. 187, 5751–5760 (2005).

  • 62.

    Harding, C. V. & Boom, W. H. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat. Rev. Microbiol. 8, 296–307 (2010).

  • 63.

    Petit, J. F., Adam, A., Wietzerbin-Falszpan, J., Lederer, E. & Ghuysen, J.-M. Chemical structure of the cell wall of Mycobacterium smegmatis. I. Isolation and partial characterization of the peptidoglycan. Biochem. Biophys. Res. Commun. 35, 478–485 (1969).

  • 64.

    Meroueh, S. O. et al. Three-dimensional structure of the bacterial cell wall peptidoglycan. Proc. Natl Acad. Sci. USA 103, 4404–4409 (2006).

  • 65.

    Carette, X. et al. Multisystem analysis of Mycobacterium tuberculosis reveals kinase-dependent remodeling of the pathogen-environment interface. mBio 9, (2018).

  • 66.

    Kaur, P. et al. LipidII interaction with specific residues of Mycobacterium tuberculosis PknB extracytoplasmic domain governs its optimal activation. Nat. Commun. 10, 1231 (2019). This article identifies the upstream molecular signal that controls an important regulator.

  • 67.

    Boutte, C. C. et al. A cytoplasmic peptidoglycan amidase homologue controls mycobacterial cell wall synthesis. eLife 5, e14590 (2016).

  • 68.

    Turapov, O. et al. Two faces of CwlM, an essential PknB substrate, in Mycobacterium tuberculosis. Cell Rep. 25, 57–67 (2018).

  • 69.

    Gee, C. L. et al. A phosphorylated pseudokinase complex controls cell wall synthesis in mycobacteria. Sci. Signal. 5, ra7 (2012).

  • 70.

    Kieser, K. J. et al. Phosphorylation of the peptidoglycan synthase PonA1 governs the rate of polar elongation in mycobacteria. PLOS Pathog. 11, e1005010 (2015).

  • 71.

    Kang, C.-M. The Mycobacterium tuberculosis serine/threonine kinases PknA and PknB: substrate identification and regulation of cell shape. Genes Dev. 19, 1692–1704 (2005).

  • 72.

    Ortega, C. et al. Mycobacterium tuberculosis Ser/Thr protein kinase B mediates an oxygen-dependent replication switch. PLoS Biol. 12, e1001746 (2014). This article describes a complete cycle of growth, stasis and reactivation, and shows how the critical cell wall regulator, PknB, plays a key role in each stage.

  • 73.

    Fontán, P. A. et al. The Mycobacterium tuberculosis sigma factor σB is required for full response to cell envelope stress and hypoxia in vitro, but it is dispensable for in vivo growth. J. Bacteriol. 191, 5628–5633 (2009).

  • 74.

    Kieser, K. J. et al. Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility. Proc. Natl Acad. Sci. USA 112, 13087–13092 (2015).

  • 75.

    Kumar, P. et al. Meropenem inhibits D,D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol. 86, 367–381 (2012).

  • 76.

    Behr, M. A. & Divangahi, M. Freund’s adjuvant, NOD2 and mycobacteria. Curr. Opin. Microbiol. 23, 126–132 (2015).

  • 77.

    Deng, J. et al. Mycobacterium tuberculosis proteome microarray for global studies of protein function and immunogenicity. Cell Rep. 9, 2317–2329 (2014).

  • 78.

    Khan, M. Z. et al. Protein kinase G confers survival advantage to Mycobacterium tuberculosis during latency-like conditions. J. Biol. Chem. 292, 16093–16108 (2017).

  • 79.

    Escuyer, V. E. et al. The role of the emba and embb gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J. Biol. Chem. 276, 48854–48862 (2001).

  • 80.

    Zhang, N. et al. The Emb proteins of mycobacteria direct arabinosylation of lipoarabinomannan and arabinogalactan via an N-terminal recognition region and a C-terminal synthetic region. Mol. Microbiol. 50, 69–76 (2003).

  • 81.

    Sharma, K. et al. Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, in vivo. J. Bacteriol. 188, 2936–2944 (2006). This article is one of the first to describe an entire regulatory pathway that controls cell wall metabolism, and to show how it affects antibiotic susceptibility.

  • 82.

    Williams, E. P., Lee, J.-H., Bishai, W. R., Colantuoni, C. & Karakousis, P. C. Mycobacterium tuberculosis SigF regulates genes encoding cell wall-associated proteins and directly regulates the transcriptional regulatory gene phoY1. J. Bacteriol. 189, 4234–4242 (2007).

  • 83.

    Hatzios, S. K. et al. Osmosensory signaling in Mycobacterium tuberculosis mediated by a eukaryotic-like Ser/Thr protein kinase. Proc. Natl Acad. Sci. USA 110, E5069–E5077 (2013).

  • 84.

    Chen, P., Ruiz, R. E., Li, Q., Silver, R. F. & Bishai, W. R. Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF. Infect. Immun. 68, 5575–5580 (2000).

  • 85.

    Sharma, K., Gupta, M., Krupa, A., Srinivasan, N. & Singh, Y. EmbR, a regulatory protein with ATPase activity, is a substrate of multiple serine/threonine kinases and phosphatase in Mycobacterium tuberculosis. FEBS J. 273, 2711–2721 (2006).

  • 86.

    Molle, V. et al. An FHA phosphoprotein recognition domain mediates protein EmbR phosphorylation by PknH, a Ser/Thr protein kinase from Mycobacterium tuberculosis. Biochem. 42, 15300–15309 (2003).

  • 87.

    Jarlier, V. & Nikaido, H. Permeability barrier to hydrophilic solutes in Mycobacterium chelonei. J. Bacteriol. 172, 1418–1423 (1990).

  • 88.

    Dahl, J. L. et al. The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc. Natl Acad. Sci. USA 100, 10026–10031 (2003).

  • 89.

    Molle, V., Brown, A. K., Besra, G. S., Cozzone, A. J. & Kremer, L. The condensing activities of the Mycobacterium tuberculosis type II fatty acid synthase are differentially regulated by phosphorylation. J. Biol. Chem. 281, 30094–30103 (2006).

  • 90.

    Vilchèze, C. et al. Phosphorylation of KasB regulates virulence and acid-fastness in Mycobacterium tuberculosis. PLOS Pathog. 10, e1004115 (2014).

  • 91.

    Slama, N. et al. Negative regulation by Ser/Thr phosphorylation of HadAB and HadBC dehydratases from Mycobacterium tuberculosis type II fatty acid synthase system. Biochem. Biophys. Res. Commun. 412, 401–406 (2011).

  • 92.

    Khan, S. et al. Phosphorylation of enoyl-acyl carrier protein reductase inha impacts mycobacterial growth and survival. J. Biol. Chem. 285, 37860–37871 (2010).

  • 93.

    Veyron-Churlet, R., Zanella-Cléon, I., Cohen-Gonsaud, M., Molle, V. & Kremer, L. Phosphorylation of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis. J. Biol. Chem. 285, 12714–12725 (2010).

  • 94.

    Deol, P. et al. Role of Mycobacterium tuberculosis Ser/Thr kinase PknF: implications in glucose transport and cell division. J. Bacteriol. 187, 3415–3420 (2005).

  • 95.

    Refaya, A. K., Sharma, D., Kumar, V., Bisht, D. & Narayanan, S. A serine/threonine kinase PknL, is involved in the adaptive response of Mycobacterium tuberculosis. Microbiol. Res. 190, 1–11 (2016).

  • 96.

    Corrales, R. M. et al. Phosphorylation of mycobacterial PcaA inhibits mycolic acid cyclopropanation: consequences for intracellular survival and for phagosome maturation block. J. Biol. Chem. 287, 26187–26199 (2012).

  • 97.

    Rao, V., Fujiwara, N., Porcelli, S. A. & Glickman, M. S. Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J. Exp. Med. 201, 535–543 (2005).

  • 98.

    Dubnau, E. et al. Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice. Mol. Microbiol. 36, 630–637 (2000).

  • 99.

    Sambandan, D. et al. Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis. mBio 4, e00222-13 (2013).

  • 100.

    Rao, V. Trans-cyclopropanation of mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis-induced inflammation and virulence. J. Clin. Invest. 116, 1660–1667 (2006).

  • 101.

    Churchyard, G. J. et al. A trial of mass isoniazid preventive therapy for tuberculosis control. N. Engl. J. Med. 370, 301–310 (2014).

  • 102.

    Belisle, J. T. et al. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276, 1420–1422 (1997).

  • 103.

    Puech, V. et al. Evidence for a partial redundancy of the fibronectin-binding proteins for the transfer of mycoloyl residues onto the cell wall arabinogalactan termini of Mycobacterium tuberculosis. Mol. Microbiol. 44, 1109–1122 (2002).

  • 104.

    Jackson, M. et al. Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Mol. Microbiol. 31, 1573–1587 (1999).

  • 105.

    Nguyen, L., Chinnapapagari, S. & Thompson, C. J. FbpA-dependent biosynthesis of trehalose dimycolate is required for the intrinsic multidrug resistance, cell wall structure, and colonial morphology of Mycobacterium smegmatis. J. Bacteriol. 187, 6603–6611 (2005).

  • 106.

    Wilkinson, R. J. et al. An increase in expression of a Mycobacterium tuberculosis mycolyl transferase gene (fbpB) occurs early after infection of human monocytes. Mol. Microbiol. 39, 813–821 (2001).

  • 107.

    Eoh, H. et al. Metabolic anticipation in Mycobacterium tuberculosis. Nat. Microbiol. 2, (2017).

  • 108.

    Galagan, J. E. et al. The Mycobacterium tuberculosis regulatory network and hypoxia. Nature 499, 178–183 (2013).

  • 109.

    Armitige, L. Y., Jagannath, C., Wanger, A. R. & Norris, S. J. Disruption of the genes encoding antigen 85a and antigen 85b of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infect. Immun. 68, 767–778 (2000).

  • 110.

    Hunter, R. L., Olsen, M. R., Jagannath, C. & Actor, J. K. Multiple roles of cord factor in the pathogenesis of primary, secondary, and cavitary tuberculosis, including a revised description of the pathology of secondary disease. Ann. Clin. Lab Sci. 36, 371–386 (2006).

  • 111.

    Lee, J. J. et al. Transient drug-tolerance and permanent drug-resistance rely on the trehalose-catalytic shift in Mycobacterium tuberculosis. Nat. Commun. 10, 2928 (2019).

  • 112.

    Cambier, C. J. et al. Mycobacteria manipulate macrophage recruitment through coordinated use of membrane lipids. Nature 505, 218–222 (2014).

  • 113.

    Barczak, A. K. et al. Systematic, multiparametric analysis of Mycobacterium tuberculosis intracellular infection offers insight into coordinated virulence. PLOS Pathog. 13, e1006363 (2017).

  • 114.

    Quigley, J. et al. The cell wall lipid PDIM contributes to phagosomal escape and host cell exit of Mycobacterium tuberculosis. mBio 8, e00148-17 (2017).

  • 115.

    Schubert, O. T. et al. Absolute proteome composition and dynamics during dormancy and resuscitation of Mycobacterium tuberculosis. Cell Host Microbe 18, 96–108 (2015).

  • 116.

    Falkinham, J. O. Mycobacterial aerosols and respiratory disease. Emerg. Infect. Dis. 9, 763–767 (2003).

  • 117.

    Ehrt, S. & Schnappinger, D. Mycobacterial survival strategies in the phagosome: defence against host stresses. Cell Microbiol. 11, 1170–1178 (2009).

  • 118.

    Roy, S. et al. Molecular basis of mycobacterial lipid antigen presentation by CD1c and its recognition by αβ T cells. Proc. Natl Acad. Sci. USA 111, E4648–E4657 (2014).

  • 119.

    Chancellor, A. et al. CD1b-restricted GEM T cell responses are modulated by Mycobacterium tuberculosis mycolic acid meromycolate chains. Proc. Natl Acad. Sci. USA 114, E10956–E10964 (2017).

  • 120.

    Moody, D. B. et al. Cd1b-Mediated T cell recognition of a glycolipid antigen generated from mycobacterial lipid and host carbohydrate during infection. J. Exp. Med. 192, 965–976 (2000).

  • 121.

    Gilleron, M. et al. Diacylated sulfoglycolipids are novel mycobacterial antigens stimulating CD1-restricted T cells during infection with Mycobacterium tuberculosis. J. Exp. Med. 199, 649–659 (2004).

  • 122.

    Busch, M. et al. Lipoarabinomannan-responsive polycytotoxic T cells are associated with protection in human tuberculosis. Am. J. Respir. Crit. Care Med. 194, 345–355 (2016).

  • 123.

    Ernst, W. A. et al. Molecular interaction of CD1b with lipoglycan antigens. Immunity 8, 331–340 (1998).

  • 124.

    Janis, E. M., Kaufmann, S. H., Schwartz, R. H. & Pardoll, D. M. Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science 244, 713–716 (1989).

  • 125.

    Van Rhijn, I. et al. A conserved human T cell population targets mycobacterial antigens presented by CD1b. Nat. Immunol. 14, 706–713 (2013).

  • 126.

    O’Garra, A. et al. The immune response in tuberculosis. Annu. Rev. Immunol. 31, 475–527 (2013).

  • 127.

    Roy, A. et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 349, g4643 (2014).

  • 128.

    Maglione, P. J. & Chan, J. How B cells shape the immune response against Mycobacterium tuberculosis. Eur. J. Immunol. 39, 676–686 (2009).

  • 129.

    Blanc, L. et al. Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. Proc. Natl Acad. Sci. USA 114, 11205–11210 (2017).

  • 130.

    Tobian, A. A. R. et al. Alternate class I MHC antigen processing is inhibited by Toll-like receptor signaling pathogen-associated molecular patterns: Mycobacterium tuberculosis 19-kDa lipoprotein, CpG DNA, and lipopolysaccharide. J. Immunol. 171, 1413–1422 (2003).

  • 131.

    Koh, K. W., Lehming, N. & Seah, G. T. Degradation-resistant protein domains limit host cell processing and immune detection of mycobacteria. Mol. Immunol. 46, 1312–1318 (2009).

  • 132.

    Saini, N. K. et al. Suppression of autophagy and antigen presentation by Mycobacterium tuberculosis PE_PGRS47. Nat. Microbiol. 1, 16133 (2016).

  • 133.

    Gagliardi, M. C. et al. Cell wall-associated alpha-glucan is instrumental for Mycobacterium tuberculosis to block CD1 molecule expression and disable the function of dendritic cell derived from infected monocyte. Cell Microbiol. 9, 2081–2092 (2007).

  • 134.

    Stenger, S., Niazi, K. R. & Modlin, R. L. Down-regulation of CD1 on antigen-presenting cells by infection with Mycobacterium tuberculosis. J. Immunol. 161, 3582–3588 (1998).

  • 135.

    Houben, D. et al. ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria. Cell Microbiol. 14, 1287–1298 (2012).

  • 136.

    van der Wel, N. et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129, 1287–1298 (2007).

  • 137.

    Conrad, W. H. et al. Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions. Proc. Natl Acad. Sci. USA 114, 1371–1376 (2017).

  • 138.

    Solomonson, M. et al. Structure of EspB from the ESX-1 type VII secretion system and insights into its export mechanism. Structure 23, 571–583 (2015).

  • 139.

    MacGurn, J. A. & Cox, J. S. A genetic screen for Mycobacterium tuberculosis mutants defective for phagosome maturation arrest identifies components of the ESX-1 secretion system. Infect. Immun. 75, 2668–2678 (2007).

  • 140.

    Portal-Celhay, C. et al. Mycobacterium tuberculosis EsxH inhibits ESCRT-dependent CD4+ T-cell activation. Nat. Microbiol. 2, 16232 (2016).

  • 141.

    Thi, E. P., Hong, C. J. H., Sanghera, G. & Reiner, N. E. Identification of the Mycobacterium tuberculosis protein PE-PGRS62 as a novel effector that functions to block phagosome maturation and inhibit iNOS expression. Cell Microbiol. 15, 795–808 (2013).

  • 142.

    Augenstreich, J. et al. ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. Cell Microbiol. 19, (2017).

  • 143.

    Rousseau, C. et al. Production of phthiocerol dimycocerosates protects Mycobacterium tuberculosis from the cidal activity of reactive nitrogen intermediates produced by macrophages and modulates the early immune response to infection. Cell Microbiol. 6, 277–287 (2004).

  • 144.

    Ishikawa, E. et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med. 206, 2879–2888 (2009).

  • 145.

    Geisel, R. E., Sakamoto, K., Russell, D. G. & Rhoades, E. R. In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette-Guérin is due principally to trehalose mycolates. J. Immunol. 174, 5007–5015 (2005).

  • 146.

    Dubée, V. et al. Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt1 by carbapenems and cephalosporins. Antimicrob. Agents Chemother. 56, 4189–4195 (2012).

  • 147.

    Gupta, R. et al. The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16, 466–469 (2010).

  • 148.

    Goude, R., Amin, A. G., Chatterjee, D. & Parish, T. The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 53, 4138–4146 (2009).

  • 149.

    de Steenwinkel, J. E. M. et al. Time–kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 65, 2582–2589 (2010).

  • 150.

    Makarov, V. et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801–804 (2009).

  • 151.

    Gao, C. et al. Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis. Sci. Rep. 6, 29717 (2016).

  • 152.

    Ando, H. et al. Downregulation of katG expression is associated with isoniazid resistance in Mycobacterium tuberculosis. Mol. Microbiol. 79, 1615–1628 (2011).

  • 153.

    Pym, A. S. et al. Regulation of catalase–peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol. Microbiol. 40, 879–889 (2001).

  • 154.

    Stanley, S. A. et al. Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32. Proc. Natl Acad. Sci. USA 110, 11565–11570 (2013).

  • 155.

    Xu, Z., Meshcheryakov, V. A., Poce, G. & Chng, S.-S. MmpL3 is the flippase for mycolic acids in mycobacteria. Proc. Natl Acad. Sci. USA 114, 7993–7998 (2017).

  • 156.

    Poce, G. et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLOS ONE 8, e56980 (2013).

  • 157.

    Stec, J. et al. Indole-2-carboxamide-based MmpL3 inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection. J. Med. Chem. 59, 6232–6247 (2016).

  • 158.

    Li, W. et al. Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3. Antimicrob. Agents Chemother. 60, 5198–5207 (2016).

  • 159.

    Li, W. et al. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 58, 6413–6423 (2014).

  • Source